ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1262

Mechanisms of Muscular Necrosis in Auto-Immune Myopathies Associated with Anti-Signal Recognition Particle and Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Antibodies: Pathogenic Role of Auto-Antibodies

Yves Allenbach1,2,3, Aude Rigolet3, Bruno Eymard4, Tanya Stojkovic4, Anthony. Behin4, Pascal Laforet4, Peter Hufnagl5, Norman Zerbe6, Thierry Maisonobe7, Kuberaka Mariampillai8, Serge Herson8, Olivier Benveniste2,3 and Werner Stenzel9, 1Neuropathology, Charite Hospital, Berlin, Germany, 2UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, 3Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, 4Department of Neurology, Myology Institute, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, 5Pathology departmen, Charite Hospital, Berlin, Germany, 6Department of Pathology, Charite Hospital, Berlin, Germany, 7Neuropathology, Pitie-Salpetriere Hospital, Paris, France, 8Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, 9Department of Neuropathology, Charite Hospital, Berlin, Germany

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Auto-immunity, autoantibodies, Myositis, polymyositis and polymyositis/dermatomyositis (PM/DM)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Myositis Autoantibodies and Disease Phenotype

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Necrotizing auto-immune myopathies (NAM) are a group of acquired idiopathic inflammatory myopathies characterized by severe muscle weakness and no or mild extra-muscular involvement. Definition of NAM is based on morphological features including fiber necrosis with no or few inflammation. Anti-SRP and anti-HMGCR auto-antibodies are specifically associated with NAM. However, to date data concerning histological features of anti-SRP or anti-HMGCR auto-antibody positive NAM patients (SRP+ or HMGCR+ NAM) are rare and mechanisms involved in fiber necrosis are totally unknown. We aim to describe the histological pattern of the skeletal muscle of a large series of SRP+ or HMGCR+NAM patients and to analyze mechanisms involved in muscle necrosis.

Methods:

Fiber necrosis was detected on combined dystrophin stain and eosin counterstaining. Fiber necrosis were manually counted and normal fibers were automatically counted using imageJ software on digitally completely scanned slides. For immunohistochemical analysis, cell density was measured. Results are compare to a myositis group of anti-Jo-1 auto-antibody positive patients. A panel of immune mediators was tested by quantitative PCR in muscle biopsies (expressed as normalized fold change relative to normal muscle).

Results: 

The percentage of fiber necrosis is higher (3.2±2.5%) in SRP+ NAM patients (n=22) compared to 1.6±1.5% in HMGCR+ NAM patients (n=19) (p=0.02) and 1.6±2.5% in Jo-1+ patients (n=17) (p=0.007). Amount of necrosis is not different in HMGCR+ NAM patients vs. Jo1+ patients but 80.7±6.7% of necrosis occurs in perifasciuclar region in Jo-1+ patients (25.3±2.8% in NAM; p<0.001). T cells and CD8+ T cells densities are higher in Jo-1+ patients (33.2±7.9 cells/mm2 and 22.3±24.6 cells/mm2) compared to NAM patients (10.2±2.3 and 4.1±6.0 cells/mm2; p=0.001) but 17.7% of NAM patients harbored significant T cells infiltrates (>20 cells/mm2). A diffuse MHC-I expression was observed in 22.7% of NAM patient vs. 87% in Jo1+ patients (p<0.001). In NAM patients T cells, CD8+ T cell densities are correlated with amount of necrosis (r=0.5 and r=0.4; p<0.01) and an up-regulation of IFN-γ gene expression is observed in NAM patients (SRP+ (n=7) and HMGCR+(n=7)).

On the other hand, a Th-2 immune polarization is observed in SRP+ (n=7) and HMGCR+ (n=7) NAM patients attested by the up-regulation of STAT6expression (11.5±5.1). In the same line 95.2% of NAM patients harbor complement membrane attack complex (C5b-9) deposits with 13.8±16.1% of muscle fibers decorated by C5b-9. Sarcolemmal C1q and IgG deposits are observed in all tested NAM patients (n=3). 

Conclusion:

SRP+ and HMGCR+ NAM patients present mostly a NAM pattern with a randomly distributed necrosis (contrary to Jo-1+ patients) more pronounced in SRP+ patients. Nevertheless a subgroup of patients presents inflammatory infiltrates which could be involved partly in muscular necrosis. In addition the Th-2 immune response with signs of classical complement pathway activation suggests the pathogenic role of auto-antibodies.


Disclosure:

Y. Allenbach,
None;

A. Rigolet,
None;

B. Eymard,
None;

T. Stojkovic,
None;

A. Behin,
None;

P. Laforet,
None;

P. Hufnagl,
None;

N. Zerbe,
None;

T. Maisonobe,
None;

K. Mariampillai,
None;

S. Herson,
None;

O. Benveniste,
None;

W. Stenzel,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mechanisms-of-muscular-necrosis-in-auto-immune-myopathies-associated-with-anti-signal-recognition-particle-and-anti-3-hydroxy-3-methylglutaryl-coenzyme-a-reductase-antibodies-pathogenic-role-of-auto/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology